Format
Sort by
Items per page

Send to

Choose Destination

Best matches for OXYCODONE/AE:

Oxycodone for neuropathic pain in adults. Gaskell H et al. Cochrane Database Syst Rev. (2016)

Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial. Riley J et al. J Pain Symptom Manage. (2015)

The Misuse of Prescription Opioids: A Threat for Europe? van Amsterdam J et al. Curr Drug Abuse Rev. (2015)

Search results

Items: 1 to 20 of 689

1.
2.

Bashing Big Pharma.

Van Way CW 3rd.

Mo Med. 2019 Mar-Apr;116(2):80-82. No abstract available.

3.

Delta-opioid receptor antagonist naltrindole reduces oxycodone addiction and constipation in mice.

Yang PP, Yeh TK, Loh HH, Law PY, Wang Y, Tao PL.

Eur J Pharmacol. 2019 Jun 5;852:265-273. doi: 10.1016/j.ejphar.2019.04.009. Epub 2019 Apr 6.

PMID:
30959048
4.

Oxycodone's Unparalleled Addictive Potential: Is it Time for a Moratorium?

Remillard D, Kaye AD, McAnally H.

Curr Pain Headache Rep. 2019 Feb 28;23(2):15. doi: 10.1007/s11916-019-0751-7.

PMID:
30820686
5.

Case 6-2019: A 29-Year-Old Woman with Nausea, Vomiting, and Diarrhea.

Walley AY, Wakeman SE, Eng G.

N Engl J Med. 2019 Feb 21;380(8):772-779. doi: 10.1056/NEJMcpc1816407. No abstract available.

6.

Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain.

Patel J, Lucas CJ, Margalit M, Martin JH.

J Pain Palliat Care Pharmacother. 2018 Jun - Sep;32(2-3):116-123. doi: 10.1080/15360288.2018.1545725. Epub 2019 Feb 8.

PMID:
30735070
7.

The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation.

Leppert W, Zajaczkowska R, Wordliczek J.

Expert Opin Pharmacother. 2019 Apr;20(5):511-522. doi: 10.1080/14656566.2018.1561863. Epub 2019 Jan 9. Review.

PMID:
30625013
8.

Risk factors of opioid-induced adverse reactions in elderly male outpatients of Korea Veterans Hospital.

Kim JY, Kim JH, Yee J, Song SJ, Gwak HS.

BMC Geriatr. 2018 Nov 29;18(1):293. doi: 10.1186/s12877-018-0990-1.

9.

Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).

Meske D, Kopecky EA, Passik S, Shram MJ.

J Opioid Manag. 2018 Sep/Oct;14(5):359-372. doi: 10.5055/jom.2018.0468.

PMID:
30387859
10.

At-a-glance - The role of opioid toxicity in suicide deaths in Alberta, 2000 to 2016.

Chan EYL, McDonald BM, Brooks-Lim E, Jones GR, Klein KB, Svenson LW.

Health Promot Chronic Dis Prev Can. 2018 Sep;38(9):343-347. doi: 10.24095/hpcdp.38.9.07. English, French.

11.

Correlations between population-levels of prescription opioid dispensing and related deaths in Ontario (Canada), 2005-2016.

Fischer B, Jones W, Varatharajan T, Malta M, Kurdyak P.

Prev Med. 2018 Nov;116:112-118. doi: 10.1016/j.ypmed.2018.09.001. Epub 2018 Sep 11.

PMID:
30217407
12.

Adverse effects of modified release oxycodone/naloxone in patients with moderate to severe liver impairment.

Pattullo V, Pattullo GG, Strasser SI.

Med J Aust. 2018 Sep 17;209(6):279-280. No abstract available.

PMID:
30208822
13.

Commonly Initiated Opioids and Risk of Fracture Hospitalizations in United States Nursing Homes.

Hunnicutt JN, Hume AL, Liu SH, Ulbricht CM, Tjia J, Lapane KL.

Drugs Aging. 2018 Oct;35(10):925-936. doi: 10.1007/s40266-018-0583-x.

PMID:
30187291
14.

Conditional power for assessing population interventions.

Walker AM, Coplan PM, Beachler DC.

J Comp Eff Res. 2018 Oct;7(10):1027-1035. doi: 10.2217/cer-2018-0053. Epub 2018 Aug 22.

15.

Oxycodone versus sufentanil in adult patient-controlled intravenous analgesia after abdominal surgery: A prospective, randomized, double-blinded, multiple-center clinical trial.

Han L, Su Y, Xiong H, Niu X, Dang S, Du K, Li Q, Liu J, Zhang P, Li S.

Medicine (Baltimore). 2018 Aug;97(31):e11552. doi: 10.1097/MD.0000000000011552.

16.

Opioids and Cardiac Arrhythmia: A Literature Review.

Behzadi M, Joukar S, Beik A.

Med Princ Pract. 2018;27(5):401-414. doi: 10.1159/000492616. Epub 2018 Aug 2. Review.

17.

Methylnaltrexone-Associated Bowel Perforation in Postoperative Opioid-Induced Constipation and Ogilvie Syndrome: A Case Report.

Blackney KA, Kamdar NV, Liu CA, Edwards DA.

A A Pract. 2019 Jan 15;12(2):44-46. doi: 10.1213/XAA.0000000000000840.

PMID:
30020107
18.

Oral oxycodone for pain after caesarean section: A randomized comparison with nurse-administered IV morphine in a pragmatic study.

Niklasson B, Arnelo C, Öhman SG, Segerdahl M, Blanck A.

Scand J Pain. 2015 Apr 1;7(1):17-24. doi: 10.1016/j.sjpain.2015.01.003.

PMID:
29911601
19.

Effect of continuous intravenous oxycodone infusion in opioid-naïve cancer patients with dyspnea.

Yamamoto Y, Watanabe H, Sakurai A, Deguchi Y, Hirano S, Okumura Y, Kumon A, Watanabe N, Osada T, Yamamura K, Odagiri T.

Jpn J Clin Oncol. 2018 Aug 1;48(8):748-752. doi: 10.1093/jjco/hyy079.

PMID:
29893883
20.

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.

Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P.

Cochrane Database Syst Rev. 2018 Jun 5;6:CD006332. doi: 10.1002/14651858.CD006332.pub3. Review.

Supplemental Content

Loading ...
Support Center